Proteomics International Laboratories Ltd (PIQ.AX) March 2024 Quarterly Activities Report

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2024.

Key Highlights

- Institutional Placement raises A$6.5m: Placement to new and existing institutional investors added global reach to the share register and strengthened Company balance sheet

- Update on commercialisation of PromarkerD in the USA: Work is continuing toward a national launch of PromarkerD, the predictive blood test for diabetic kidney disease (DKD), in the USA

- Latest results validate biomarkers for PromarkerEndo blood test for endometriosis: Critical milestone achieved for PromarkerEndo with biomarker panel clinically validated in an independent patient group

- Agreement signed with University of Oxford to validate PromarkerEndo test for endometriosis: Proteomics International to acquire 600 patient plasma samples for further clinical validation of its diagnostic blood test

- Latest results validate biomarkers for PromarkerEso blood test for oesophageal adenocarcinoma: Critical milestone achieved for PromarkerEso, with biomarker panel clinically validated in second independent patient group

- Proteomics International retains its ISO 13485 certification: international standard recognises safety and quality management systems in the manufacture of medical devices, such as PromarkerD

- European patent granted for OxiDx technology: Proteomics International's subsidiary OxiDx Pty Ltd granted a patent in 19 major European countries for its platform technology to measure oxidative stress using a simple fingerprick blood test

*To view the full Quarterly Report, please visit:
https://abnnewswire.net/lnk/71G425KY

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel 
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367 
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

Lisa Barnes
Public Relations
Profile Media
T: +61 416 583 672
E: lisab@profilemedia.com.au

News Provided by ABN Newswire